
ERRATUM

Perspectives and opportunities for nanomedicine in the management of atherosclerosis

Mark E. Lobatto, Valentin Fuster, Zahi A. Fayad and Willem J. M. Mulder

Nature Reviews Drug Discovery **10**, 835–852 (2011) | doi:10.1038/nrd3578

The following sentence was inadvertently duplicated on page 835:

Subsequently, several other nanomedicinal therapeutics have been approved for clinical use, including an albumin-bound nanoparticle delivering paclitaxel for the treatment of breast cancer (Abraxane; Abraxis BioScience) and liposomal amphotericin B for the treatment of fungal infections (AmBisome; Astellas Pharma).

This has been removed from the online version.